Samsung BioLogics made an announcement on the 7th that it has signed a contract with US Engineers for consignment development and production (CDMO).
Under the deal, Samsung BioLogics will provide CDMO services for COVID-19 single antibody therapy under development by Enzolitics and a single antibody treatment for human immunodeficiency virus (HIV).
It provides one-stop support for cell line development, clinical material production, and clinical trial planning application (IND) support process.
Contracts will also be discussed for other antibody treatments under development by Enzoletics. Based on the artificial intelligence (AI) platform, Enzolitics is developing antibody treatments to respond to mutated viruses by targeting certain parts that remain unchanged in the virus.
Samsung BioLogics plans to support the development of cell lines of Enzoletics through the CDO (Pharmaceutical Consignment Development) R&D Center in San Francisco, USA.
Reporter Lee Ji-sun stockmk2020@gmail.com